Trial ID or NCT#

NCT05144789

Status

recruiting iconRECRUITING

Purpose

This study will investigate the anti-anhedonic efficacy of a novel neurostimulation strategy termed accelerated intermittent theta burst stimulation (aiTBS) in participants with treatment resistant depression (TRD) or BD. aiTBS is a novel application of repetitive transcranial magnetic stimulation (TMS), that induces remission in 90% of individuals with severe, treatment resistant MDD in 1-5 days.

Official Title

Personalized Therapeutic Neuromodulation for Anhedonic Depression

Eligibility Criteria

Ages Eligible for Study: 18 Years to 80 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

David Spiegel
David Spiegel
Psychiatrist
Jack, Lulu and Sam Willson Professor of Medicine

Contact us to find out if this trial is right for you.

CONTACT

Romina Nejad, MSc
(650) 497-3933